Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 4/20 | 0.35 |
| ▸ | CTSK | P43235 | 4/20 | 0.35 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21058382 | 0.85 | ITGB3 (0.38) | KDM1ABACE1ITGB3ITGA2BACE | |
| SCHEMBL21138668 | 0.85 | ITGB3 (0.38) | KDM1ABACE1ITGB3ITGA2BACE | |
| SCHEMBL21058353 | 0.74 | ACE (0.48) | ACEEPHX2CTSSCTSKKLK5 | |
| SCHEMBL29777479 | 0.74 | ACE (0.48) | ACEEPHX2CTSSCTSKKLK5 | |
| SCHEMBL14343069 | 0.71 | ITGB3 (0.45) | KDM1ABACE1ITGB3ITGA2BACE | |
| SCHEMBL14343099 | 0.71 | ITGB3 (0.45) | KDM1ABACE1ITGB3ITGA2BACE | |
| SCHEMBL1087185 | 0.71 | ITGB3 (0.65) | ITGB3ITGA2BACEHDAC8CTSS | |
| SCHEMBL16909032 | 0.71 | ITGB3 (0.65) | ITGB3ITGA2BACEHDAC8CTSS | |
| SCHEMBL14343235 | 0.71 | ITGB3 (0.65) | ITGB3ITGA2BACEHDAC8CTSS | |
| SCHEMBL7338573 | 0.70 | KLK5 (0.50) | ITGB3ITGA2BACEHDAC8CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | KDM1A 3807/4885BACE1 1624/4885ITGB3 1429/4885 |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | OGT, UGGT1, GLA | KDM1A 3807/4885BACE1 1624/4885ITGB3 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.